Supplementary Table 1 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 30K, BRAF mutant cell lines utilized in the RPPA analysis. Cells were lysed at approximately 70% confluence in 10% serum. Of note, Colo201 and Colo205 are derived from the same colon cancer patient, as are HT29 and WiDr. Cell lines were obtained from the American Type Culture Collection, or the Ludwig Institute of Cancer Research. Cell line identities were confirmed by STR testing, and were verified to be Mycoplasma-free. All lines were grown in DMEM/F-12, or RPMI1640 medium supplemented with 10% FBS and 2 mmol/L glutamine or MEM, (10�S, sodium pyruvate, L-glutamine, vitamins, and nonessential amino acids). Cells were incubated in 5% CO2 at 37{degree sign}C.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361881408